RxDoctor Payments Data

Gregory Moore, MD

Interventional Pain Medicine · Eugene, ORNPI 1457496705

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $238,613 of the $377,163 with a category attached, or 63.3%. 28 manufacturers reported payments, led by Relievant Medsystems, Inc. at 42.2% of the total. Among interventional pain medicine clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$377,163in general payments, 2019–2025

Across 796 payments — averaging $473.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Relievant Medsystems, Inc.$159K
  • Boston Scientific$134K
  • Aurora Spine, Inc.$28K
  • Medtronic$16K
  • Abbott$15K
  • MML US, Inc.$10K
  • plus $15K from 22 others
$1,369,444in research payments, 2019–2025

Across 247 payments — averaging $5544.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$531K
  • Nalu Medical, Inc.$348K
  • MML US, Inc.$212K
  • Abbott$115K
  • Relievant Medsystems, Inc.$56K
  • Vertex$52K
  • plus $55K from 3 others

What the payments were for

  • Consulting fees$85,58923%
  • Speaking & faculty fees$238,61363%
  • Travel & lodging$31,9798%
  • Food & beverage$19,9595%
  • Education$1,0240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$377,163 in reported general payments places this provider in the 95th percentile of 22 interventional pain medicine providers in Oregon.

See all interventional pain medicine providers in Oregon

Medicare billing

Part B allowed, 2024
$315,794
Medicare patients
690
Services billed
7,491

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gabapentin27$522
Oxycodone Hcl15$175

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Eugene

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →